MX2023014174A - Sales y formulaciones de fenil pirrol aminoguanidina. - Google Patents
Sales y formulaciones de fenil pirrol aminoguanidina.Info
- Publication number
- MX2023014174A MX2023014174A MX2023014174A MX2023014174A MX2023014174A MX 2023014174 A MX2023014174 A MX 2023014174A MX 2023014174 A MX2023014174 A MX 2023014174A MX 2023014174 A MX2023014174 A MX 2023014174A MX 2023014174 A MX2023014174 A MX 2023014174A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- phenyl pyrrole
- aminoguanidine salts
- pyrrole aminoguanidine
- salts
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- ZIKCHNCVFRYIRB-UHFFFAOYSA-N 2-aminoguanidine 2-phenyl-1H-pyrrole Chemical class NNC(N)=N.C1=CNC(C=2C=CC=CC=2)=C1 ZIKCHNCVFRYIRB-UHFFFAOYSA-N 0.000 title 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- -1 phenyl pyrrole aminoguanidine compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180708 | 2021-06-21 | ||
| EP21180702 | 2021-06-21 | ||
| EP21209855 | 2021-11-23 | ||
| PCT/EP2022/066906 WO2022268825A1 (en) | 2021-06-21 | 2022-06-21 | Phenyl pyrrole aminoguanidine salts and formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014174A true MX2023014174A (es) | 2024-03-01 |
Family
ID=84544160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014174A MX2023014174A (es) | 2021-06-21 | 2022-06-21 | Sales y formulaciones de fenil pirrol aminoguanidina. |
| MX2023014177A MX2023014177A (es) | 2021-06-21 | 2022-06-21 | Sales de fenil-pirrol-aminoguanida y polimorfos de sales de fenil-pirrol-aminoguanidinio. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014177A MX2023014177A (es) | 2021-06-21 | 2022-06-21 | Sales de fenil-pirrol-aminoguanida y polimorfos de sales de fenil-pirrol-aminoguanidinio. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12661336B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4359383A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024522817A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240024818A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022296767A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023026909A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3220756A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3045575T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL309102A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2023014174A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2022268825A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3175172A1 (en) * | 2020-03-31 | 2021-10-07 | Synact Pharma Aps | Treatment of symptomatic viral diseases |
| IL309102A (en) * | 2021-06-21 | 2024-02-01 | Synact Pharma Aps | Salts and formulations of phenyl pyrrole aminoguanidine |
| EP4522160A1 (en) * | 2022-05-12 | 2025-03-19 | SynAct Pharma ApS | Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis |
| EP4637921A1 (en) * | 2022-12-21 | 2025-10-29 | SynAct Pharma ApS | Polymorph of phenyl pyrrole hydrazine carboximidamide compound |
| AU2024398488A1 (en) | 2023-12-11 | 2026-06-04 | Synact Pharma Aps | Treatment of subpopulation of patients with rheumatoid arthritis |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604348D0 (sv) | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| AU7464998A (en) | 1997-10-27 | 1999-05-17 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| HK1044954B (en) | 1999-03-29 | 2008-11-21 | The Procter & Gamble Company | Melanocortin receptor ligands |
| WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| AU6605800A (en) | 1999-07-16 | 2001-02-05 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| WO2001055106A2 (en) | 2000-01-28 | 2001-08-02 | Melacure Therapeutics Ab | Novel melanocortin receptor agonists and antagonists |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| KR100440370B1 (ko) | 2000-04-01 | 2004-07-19 | (주)명문엘씨 | 2중 사출에 의한 밀폐용기 뚜껑 |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| US20030069169A1 (en) | 2001-03-02 | 2003-04-10 | Macor John E. | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| CA2363528A1 (en) | 2001-11-19 | 2003-05-19 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immediate release tablet containing naproxen sodium |
| GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| SI2348016T1 (sl) | 2006-06-09 | 2016-10-28 | Synact Pharma Aps | Derivati fenil pirol aminogvanidina |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| EP2045250A1 (en) | 2007-09-26 | 2009-04-08 | Action Pharma A/S | Ring-substituted phenyl pyrrole aminoguanidine derivatives |
| WO2009071101A1 (en) | 2007-12-07 | 2009-06-11 | Action Pharma A/S | N-modified aminoguanidine derivatives |
| WO2009074157A1 (en) | 2007-12-13 | 2009-06-18 | Action Pharma A/S | Fully-modified phenyl pyrrole aminoguanidines |
| US10387927B2 (en) | 2010-01-15 | 2019-08-20 | Dell Products L.P. | System and method for entitling digital assets |
| EA201290860A1 (ru) | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| JP2011190199A (ja) | 2010-03-12 | 2011-09-29 | Hideto Nakamura | 関節リウマチ薬 |
| US9662807B2 (en) | 2011-12-21 | 2017-05-30 | GKN Aerospace Services Structures, Corp. | Method for forming a fabric preform for a composite material by separately tensioning tows |
| WO2014060606A1 (en) | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| US9917808B2 (en) | 2013-03-14 | 2018-03-13 | International Business Machines Corporation | Grouping electronic messages |
| WO2015162483A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2015162486A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
| WO2017141343A1 (ja) | 2016-02-16 | 2017-08-24 | 三菱電機株式会社 | 圧縮機 |
| ES2899200T3 (es) | 2018-06-22 | 2022-03-10 | Synact Pharma Aps | Tratamiento de proteinuria |
| WO2020107221A1 (en) | 2018-11-27 | 2020-06-04 | Tsinghua University | Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof |
| HUE059638T2 (hu) * | 2019-05-10 | 2022-12-28 | Synact Pharma Aps | Ízületi gyulladásos betegségek kombinált kezelése |
| CA3175172A1 (en) * | 2020-03-31 | 2021-10-07 | Synact Pharma Aps | Treatment of symptomatic viral diseases |
| CN113730797B (zh) | 2020-05-29 | 2023-05-16 | 创领心律管理医疗器械(上海)有限公司 | 电极板及可穿戴式除颤设备 |
| IL309102A (en) * | 2021-06-21 | 2024-02-01 | Synact Pharma Aps | Salts and formulations of phenyl pyrrole aminoguanidine |
-
2022
- 2022-06-21 IL IL309102A patent/IL309102A/en unknown
- 2022-06-21 JP JP2023578136A patent/JP2024522817A/ja active Pending
- 2022-06-21 WO PCT/EP2022/066906 patent/WO2022268825A1/en not_active Ceased
- 2022-06-21 CA CA3220756A patent/CA3220756A1/en active Pending
- 2022-06-21 KR KR1020237043107A patent/KR20240024818A/ko active Pending
- 2022-06-21 AU AU2022296767A patent/AU2022296767A1/en active Pending
- 2022-06-21 IL IL309104A patent/IL309104A/en unknown
- 2022-06-21 MX MX2023014174A patent/MX2023014174A/es unknown
- 2022-06-21 EP EP22735858.7A patent/EP4359383A1/en active Pending
- 2022-06-21 WO PCT/EP2022/066884 patent/WO2022268814A1/en not_active Ceased
- 2022-06-21 EP EP22737436.0A patent/EP4359076B1/en active Active
- 2022-06-21 AU AU2022300305A patent/AU2022300305A1/en active Pending
- 2022-06-21 CA CA3220753A patent/CA3220753A1/en active Pending
- 2022-06-21 KR KR1020247000873A patent/KR20240024177A/ko active Pending
- 2022-06-21 ES ES22737436T patent/ES3045575T3/es active Active
- 2022-06-21 JP JP2023578832A patent/JP2024523459A/ja active Pending
- 2022-06-21 EP EP25194012.8A patent/EP4684835A3/en active Pending
- 2022-06-21 BR BR112023026909A patent/BR112023026909A2/pt not_active Application Discontinuation
- 2022-06-21 MX MX2023014177A patent/MX2023014177A/es unknown
- 2022-08-23 US US17/821,500 patent/US12661336B2/en active Active
- 2022-12-14 US US18/065,702 patent/US20230114865A1/en active Pending
-
2024
- 2024-05-29 US US18/676,679 patent/US12239631B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4359076A1 (en) | 2024-05-01 |
| JP2024523459A (ja) | 2024-06-28 |
| AU2022296767A1 (en) | 2024-02-01 |
| AU2022300305A1 (en) | 2024-01-25 |
| EP4359076C0 (en) | 2025-08-06 |
| US20230114865A1 (en) | 2023-04-13 |
| KR20240024818A (ko) | 2024-02-26 |
| EP4359076B1 (en) | 2025-08-06 |
| IL309104A (en) | 2024-02-01 |
| JP2024522817A (ja) | 2024-06-21 |
| US12239631B2 (en) | 2025-03-04 |
| EP4684835A2 (en) | 2026-01-28 |
| US20230271922A9 (en) | 2023-08-31 |
| WO2022268825A1 (en) | 2022-12-29 |
| ES3045575T3 (en) | 2025-11-28 |
| CA3220753A1 (en) | 2022-12-29 |
| US20230002319A1 (en) | 2023-01-05 |
| IL309102A (en) | 2024-02-01 |
| WO2022268814A1 (en) | 2022-12-29 |
| BR112023026909A2 (pt) | 2024-03-05 |
| MX2023014177A (es) | 2024-03-26 |
| KR20240024177A (ko) | 2024-02-23 |
| US12661336B2 (en) | 2026-06-23 |
| US20240335423A1 (en) | 2024-10-10 |
| EP4684835A3 (en) | 2026-04-08 |
| CA3220756A1 (en) | 2022-12-29 |
| EP4359383A1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4684835A3 (en) | Phenyl pyrrole aminoguanidine salts and formulations | |
| MY206908A (en) | Cationic lipid compound, composition containing same and use thereof | |
| WO2022125616A8 (en) | Dialkyl tryptamines and their therapeutic uses | |
| MX2024000299A (es) | Compuestos antivirales. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| GEP20125415B (en) | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) | |
| SG10201407538WA (en) | Intravenous formulations of neurokinin-1 antagonists | |
| MY140638A (en) | New heterocyclic compounds, which are active as inhibitors of beta-lactamases | |
| ZA202500422B (en) | Nitrogen-containing compound and use thereof | |
| MX2025013480A (es) | Compuestos heterocíclicos que contienen nitrógeno y uso de los mismos | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2022012881A (es) | Inhibidores de replicacion del virus de inmunodeficiencia humana. | |
| GEP20125389B (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| TN2022000092A1 (en) | Oral complement factor d inhibitors | |
| PT1105105E (pt) | Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois | |
| IN2012DN04868A (cg-RX-API-DMAC7.html) | ||
| MY139704A (en) | Naphthalene derivatives for use as histamine-3-receptor ligands | |
| PH12022550349B1 (en) | Oral pharmaceutical composition containing heterocyclic compound | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| WO2020016302A8 (en) | A xinafoate salt of a jak inhibiting compound | |
| PH12022550859A1 (en) | 2-azaspiro[3.4]octane derivatives as m4 agonists | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
| MX2025014275A (es) | Derivado de pirrolopirimidina y uso del mismo en medicina |